Picture loading failed.

Anti-IL9 therapeutic antibody (Pre-made Enokizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Enokizumab, also known as MEDI-528, is a humanized IgG1κ type monoclonal antibody direct against the cytokine interleukin-9 (IL-9). This drug was developed by MedImmune and has been investigated in the treatment for asthma.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-185-1mg 1mg 3090
GMP-Bios-ab-185-10mg 10mg 21890
GMP-Bios-ab-185-100mg 100mg 148000
GMP-Bios-ab-185-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL9 therapeutic antibody (Pre-made Enokizumab biosimilar,Whole mAb)
INN Name Enokizumab
TargetIL9
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesGenaera Corporation;Ludwig Institute for Cancer Research;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAsthma
Development Techna